Johnson & Johnson CFO Joseph Wolk said the pause in its COVID-19 vaccine trial due to an unexplained illness in a study participant should not be seen as something unusual given the large size of the study group and sought to reassure the public that “every scientific, medical, and ethical standard is being applied here” as safety protocols are followed.
In an appearance on CNBC’s Squawk Box, Wolk responded to a question about Johnson & Johnson’s announcement on Monday that the company temporarily paused further dosing in all its COVID-19 vaccine candidate clinical trials. The company said the participant’s illness was being reviewed by an independent data safety monitoring board and the company’s internal clinical and safety physicians.
